Your browser doesn't support javascript.
loading
Approaches to the Assessment of Clinical Benefit of Treatments for Conditions That Have Heterogeneous Symptoms and Impacts: Potential Applications in Rare Disease.
Murray, Lindsey T; Howell, Timothy A; Matza, Louis S; Eremenco, Sonya; Adams, Heather R; Trundell, Dylan; Coons, Stephen Joel.
Afiliação
  • Murray LT; Critical Path Institute, Tucson, AZ, USA. Electronic address: lmurray@c-path.org.
  • Howell TA; Evidera, Bethesda, MD, USA.
  • Matza LS; Evidera, Bethesda, MD, USA.
  • Eremenco S; Critical Path Institute, Tucson, AZ, USA.
  • Adams HR; University of Rochester, Rochester, NY, USA.
  • Trundell D; Roche Products Ltd, Hertfordshire, England, UK.
  • Coons SJ; Critical Path Institute, Tucson, AZ, USA.
Value Health ; 26(4): 547-553, 2023 04.
Article em En | MEDLINE | ID: mdl-36455827
OBJECTIVES: Evaluating the clinical benefit of interventions for conditions with heterogeneous symptom and impact presentations is challenging. The same condition can present differently across and within individuals over time. This occurs frequently in rare diseases. The purpose of this review was to identify (1) assessment approaches used in clinical trials to address heterogeneous manifestations that could be relevant in rare disease research and (2) US Food and Drug Administration (FDA)-approved labeling claims that used these approaches. METHODS: A targeted literature review was conducted examining peer-reviewed publications and FDA-approved labeling claims from January 2002 to July 2020, focusing on claims incorporating clinical outcome assessments. Approaches were then assessed for their potential application in rare diseases. RESULTS: A total of 6 assessment approaches were identified: composite or other multicomponent endpoints, multidomain responder index, most bothersome symptom (MBS), goal attainment scaling, sliding dichotomy, and adequate relief. A total of 59 FDA-approved labeling claims associated with these approaches were identified: composite or other multicomponent endpoints (n=49), MBS (n=9), and adequate relief (n=1). A total of 10 FDA-approved labeling claims, all using multicomponent endpoints, were identified for rare diseases. CONCLUSIONS: Multicomponent, MBS, and adequate relief have been included in FDA-approved labeling claims. Multicomponent endpoints, including composite endpoints, were the most frequent way to address heterogeneous manifestations of both common and rare diseases. MBS may be acceptable to regulators, whereas multidomain responder index is unlikely to be. The goal attainment scaling and adequate relief approaches may have potential utility in rare disease trials, assuming the theoretical and statistical challenges inherent in each approach are managed.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Rotulagem de Produtos / Doenças Raras Tipo de estudo: Diagnostic_studies Limite: Humans País/Região como assunto: America do norte Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Rotulagem de Produtos / Doenças Raras Tipo de estudo: Diagnostic_studies Limite: Humans País/Região como assunto: America do norte Idioma: En Ano de publicação: 2023 Tipo de documento: Article